Zobrazeno 1 - 10
of 824
pro vyhledávání: '"Yi, Long"'
Autor:
Cunte Chen, Si-Yang Maggie Liu, Yedan Chen, Qiuxiang Ou, Hua Bao, Ling Xu, Yikai Zhang, Wenzhao Zhong, Qing Zhou, Xue-Ning Yang, Yang Shao, Yi-Long Wu, Si-Yang Liu, Yangqiu Li
Publikováno v:
JCI Insight, Vol 7, Iss 1 (2022)
Herein, we characterize the landscape and prognostic significance of the T cell receptor (TCR) repertoire of early-stage non–small cell lung cancer (NSCLC) for patients with an epidermal growth factor receptor (EGFR) mutation. β Chain TCR sequenci
Externí odkaz:
https://doaj.org/article/e9d0b5de38f04d528dbf30a383dbdcae
Autor:
Jarushka Naidoo, Scott Antonia, Yi-Long Wu, Byoung Chul Cho, Piruntha Thiyagarajah, Helen Mann, Michael Newton, Corinne Faivre-Finn
Publikováno v:
Journal of Thoracic Oncology. 18:657-663
Autor:
Gilberto de Castro, Iveta Kudaba, Yi-Long Wu, Gilberto Lopes, Dariusz M. Kowalski, Hande Z. Turna, Christian Caglevic, Li Zhang, Boguslawa Karaszewska, Konstantin K. Laktionov, Vichien Srimuninnimit, Igor Bondarenko, Kaoru Kubota, Rinee Mukherjee, Jianxin Lin, Fabricio Souza, Tony S.K. Mok, Byoung Chul Cho
Publikováno v:
Journal of Clinical Oncology. 41:1986-1991
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co‐primary or secondary analyses are not yet available. Clinical
Autor:
Tetsuya Mitsudomi, Daniel Tan, James Chih-Hsin Yang, Myung-Ju Ahn, Ullas Batra, Byoung-Chul Cho, Gerardo Cornelio, Tony Lim, Tony Mok, Kumar Prabhash, Thanyanan Reungwetwattana, Sheng-Xiang Ren, Navneet Singh, Shinichi Toyooka, Yi-Long Wu, Pan-Chyr Yang, Yasushi Yatabe
Publikováno v:
Journal of Thoracic Oncology. 18:436-446
Autor:
Roy S. Herbst, Yi-Long Wu, Thomas John, Christian Grohe, Margarita Majem, Jie Wang, Terufumi Kato, Jonathan W. Goldman, Konstantin Laktionov, Sang-We Kim, Chong-Jen Yu, Huu Vinh Vu, Shun Lu, Kye Young Lee, Guzel Mukhametshina, Charuwan Akewanlop, Filippo de Marinis, Laura Bonanno, Manuel Domine, Frances A. Shepherd, Damien Urban, Xiangning Huang, Ana Bolanos, Marta Stachowiak, Masahiro Tsuboi
Publikováno v:
Journal of Clinical Oncology. 41:1830-1840
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Tr
Autor:
Chong-Rui Xu, Qixun Chen, Chengzhi Zhou, Lin Wu, Wen Li, Huizhong Zhang, Yongsheng Li, Fei Xu, Jianping Xiong, Qiming Wang, Haibo Zhang, Yuequan Jiang, Haitao Yin, Qingchen Wu, Qiangsheng Dai, Jian Hu, Jianhua Chen, Jian Zhang, Gang Wu, Jun Yin, Jianfu Zhao, Baogang Liu, Jianzhen Shan, Liming Sheng, Qunqing Chen, Zhengxiang Han, Huaqiu Shi, Yimin Liu, Jun Chen, Yi-Long Wu
Publikováno v:
Translational Lung Cancer Research. 12:127-140
Autor:
Chan-Yuan, Zhang, Hao, Sun, Jun-Wei, Su, Yu-Qing, Chen, Shi-Ling, Zhang, Ming-Ying, Zheng, Yu-Fa, Li, Jie, Huang, Chao, Zhang, Zai-Xian, Tai, Miao, Cai, Xu-Chao, Zhang, Jian, Su, Chong-Rui, Xu, Hong-Hong, Yan, Hua-Jun, Chen, Yi-Long, Wu, Jin-Ji, Yang
Publikováno v:
Lung Cancer. 175:68-78
Transformed small-cell lung cancer (T-SCLC) has an extremely poor prognosis, and no remedies based on immunotherapy have been evaluated among T-SCLC patients. We retrospectively analysed the efficacy and safety of combining atezolizumab with chemothe
Autor:
Parneet Cheema, Byoung Chul Cho, Helano Freitas, Mariano Provencio, Yuh Min Chen, Sang-We Kim, Yi-Long Wu, Antonio Passaro, Claudio Martin, Marcello Tiseo, Gee-Chen Chang, Keunchil Park, Benjamin Solomon, Otto Burghuber, Janessa Laskin, Ziping Wang, Sung Yong Lee, Yanping Hu, Johan Vansteenkiste, He-long Zhang, Emer Hanrahan, Thomas Geldart, Rosemary Taylor, Leslie Servidio, Jingyi Li, Filippo de Marinis
Publikováno v:
Future Oncology. 19:61-75
Aim: Report the final analysis from ASTRIS, the largest real-world study of second-/later-line osimertinib in advanced/metastatic EGFR T790M non-small-cell lung cancer (NSCLC). Methods: Patients with advanced/metastatic EGFR T790M NSCLC and prior EGF
Autor:
Si-Yang Maggie Liu, Hong-Hong Yan, Xue-Wu Wei, Chang Lu, Xiao-Rong Dong, Yingying Du, Jiu-Wei Cui, Yuan Chen, Rui Ma, Bu-Hai Wang, Zhen Zhou, Shun-Dong Cang, Jin-Ji Yang, Hai-Yan Tu, Xu-Chao Zhang, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu
Publikováno v:
Clinical Lung Cancer. 23:e395-e399
With rare genetic variations having been increasingly recognized at a preclinical stage, a variety of early-phase clinical trials have been launched. Due to the low incidence rate of these variations, although the sample size of trials are small, it
Autor:
Benjamin J. Solomon, Todd M. Bauer, Sai-Hong Ignatius Ou, Geoffrey Liu, Hidetoshi Hayashi, Alessandra Bearz, Konstantin Penkov, Yi-Long Wu, Oscar Arrieta, Jacek Jassem, Anna M. Calella, Gerson Peltz, Anna Polli, Holger Thurm, Tony Mok
Publikováno v:
Journal of Clinical Oncology. 40:3593-3602
PURPOSE Lorlatinib significantly improved progression-free survival (PFS) versus crizotinib and showed robust intracranial activity in patients with previously untreated advanced ALK-positive non–small-cell lung cancer (NSCLC) in the phase III CROW